

## NEWS & VIEWS REFERENCES

### From the Ed's desk

1. Nagpal TS, Salas XR, Vallis M, Piccinini-Vallis H, Alberga AS, Bell RC, et al. Exploring weight bias internalization in pregnancy. *BMC pregnancy and childbirth* [Internet]. 2022 Jul 29 [cited 2023 Jun 6];22(1):605. Available from: <https://pubmed.ncbi.nlm.nih.gov/35906530/>
2. Mulherin K, Miller YD, Barlow FK, Diedrichs PC, Thompson R. Weight stigma in maternity care: women's experiences and care providers' attitudes. *BMC Pregnancy and Childbirth* [Internet]. 2013 Jan 22;13(1). Available from: <https://bmcpregnancychildbirth.biomedcentral.com/articles/10.1186/1471-2393-13-19>
3. Kriebs JM. Obesity in Pregnancy. *Journal of Perinatal & Neonatal Nursing*. 2014 Jan;28(1):32–40.

### Experimental hookworm infection reduces insulin resistance in people at risk of T2D

1. Pierce DR, McDonald M, Merone L, Becker L, Thompson F, Lewis C, et al. Effect of experimental hookworm infection on insulin resistance in people at risk of type 2 diabetes. *Nature Communications* [Internet]. 2023 Jul 26 [cited 2023 Aug 16];14(1).

### Aspartame Update

1. Use of non-sugar sweeteners: WHO guideline [Internet]. [www.who.int](http://www.who.int). Available from: <https://www.who.int/publications/i/item/9789240073616>
2. Health effects of the use of non-sugar sweeteners: a systematic review and meta-analysis [Internet]. [www.who.int](http://www.who.int). Available from: <https://www.who.int/publications/i/item/9789240046429>
3. World health organization. Aspartame hazard and risk assessment results released [Internet]. [www.who.int](http://www.who.int). 2023. Available from: <https://www.who.int/news/item/14-07-2023-aspartame-hazard-and-risk-assessment-results-released>
4. Naddaf M. Aspartame is a possible carcinogen: the science behind the decision. *Nature* [Internet]. 2023 Jul 14; Available from: <https://www.nature.com/articles/d41586-023-02306-0>

### Semaglutide shows promise in T1D study

1. Paresh Dandona, Chaudhuri A, Ghanim H. Semaglutide in Early Type 1 Diabetes. *The New England Journal of Medicine*. 2023 Sep 7;389(10):958–9.

### Liraglutide and Associative Learning in People with Obesity

1. Hanssen R, Rigoux L, Kuzmanovic B, Iglesias S, Kretschmer AC, Schlamann M, et al. Liraglutide restores impaired associative learning in individuals with obesity. *Nature Metabolism* [Internet]. 2023 Aug 1 [cited 2023 Sep 6];5(8):1352–63. Available from: <https://www.nature.com/articles/s42255-023-00859-y>
2. Study explores mechanism behind liraglutide-associated weight loss in obese individuals [Internet]. *News-Medical.net*. 2023 [cited 2023 Sep 6]. Available from: <https://www.news-medical.net/news/20230822/Study-explores-mechanism-behind-liraglutide-associated-weight-loss-in-obese-individuals.aspx#:~:text=The%20findings%20indicate%20that%20liraglutide>
3. Drucker, D. J. GLP-1 physiology informs the pharmacotherapy of obesity. *Mol. Metab.* 57, 101351 (2022)

## FEATURE REFERENCES

### p10-14 Diabetic Kidney Disease – what's new?

1. de Boer IH, Caramori ML, Chan JC, Heerspink HJ, Hurst C, Khunti K, et al. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. *Kidney international*. 2020;98(4):S1–S115.
2. Koye DN, Magliano DJ, Nelson RG, Pavkov ME. The Global Epidemiology of Diabetes and Kidney Disease. *Adv Chronic Kidney Dis*. 2018;25(2):121–32.
3. Organization WH. Global status report on noncommunicable diseases 2014: World Health Organization; 2014.
4. Groop PH, Thomas MC, Moran JL, Wadèn J, Thorn LM, Mäkinen VP, et al. The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. *Diabetes*. 2009;58(7):1651–8.

**p10-14 Diabetic Kidney Disease – what's new? Cont'd**

5. Orchard TJ, Secrest AM, Miller RG, Costacou T. In the absence of renal disease, 20 year mortality risk in type 1 diabetes is comparable to that of the general population: a report from the Pittsburgh Epidemiology of Diabetes Complications Study. *Diabetologia*. 2010;53(11):2312-9.
6. Afkarian M, Sachs MC, Kestenbaum B, Hirsch IB, Tuttle KR, Himmelfarb J, et al. Kidney disease and increased mortality risk in type 2 diabetes. *J Am Soc Nephrol*. 2013;24(2):302-8.
7. Schultz CJ, Neil HA, Dalton RN, Dunger DB. Risk of nephropathy can be detected before the onset of microalbuminuria during the early years after diagnosis of type 1 diabetes. *Diabetes Care*. 2000;23(12):1811-5.
8. Amin R, Widmer B, Prevost AT, Schwarze P, Cooper J, Edge J, et al. Risk of microalbuminuria and progression to macroalbuminuria in a cohort with childhood onset type 1 diabetes: prospective observational study. *Bmj*. 2008;336(7646):697-701.
9. de Boer IH, Khunti K, Sadosky T, Tuttle KR, Neumiller JJ, Rhee CM, et al. Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). *Diabetes Care*. 2022;45(12):3075-90.
10. Diabetic kidney disease - Symptoms, diagnosis and treatment | BMJ Best Practice US [Internet]. bestpractice.bmj.com. Available from: [https://bestpractice.bmj.com/topics/en-us/530#:~:text=Diabetic%20kidney%20disease%20\(DKD\)%20is](https://bestpractice.bmj.com/topics/en-us/530#:~:text=Diabetic%20kidney%20disease%20(DKD)%20is)
11. Liang S, Zhang XG, Cai GY, Zhu HY, Zhou JH, Wu J, et al. Identifying parameters to distinguish non-diabetic renal diseases from diabetic nephropathy in patients with type 2 diabetes mellitus: a meta-analysis. *PLoS One*. 2013;8(5):e64184.
12. Forbes JM, Cooper ME. Mechanisms of diabetic complications. *Physiol Rev* 2013; 93(1); 137-88.
13. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. *Am J Kidney Dis*. 2012;60(5):850-86.
14. Levey AS, Inker LA, Coresh J. GFR estimation: from physiology to public health. *Am J Kidney Dis*. 2014;63(5):820-34.
15. Levin A, Stevens PE, Bilous RW, Coresh J, De Francisco AL, De Jong PE, et al. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. *Kidney international supplements*. 2013;3(1):1-150.
16. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. *Am J Kidney Dis*. 2012;60(5):850-86
17. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. *N Engl J Med*. 2012;367(1):20-9.
18. Molitch ME, Steffes M, Sun W, Rutledge B, Cleary P, de Boer IH, et al. Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. *Diabetes Care*. 2010;33(7):1536-43.
19. Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. *Diabetes*. 2006;55(6):1832-9.
20. de Boer IH, Rue TC, Cleary PA, Lachin JM, Molitch ME, Steffes MW, et al. Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. *Arch Intern Med*. 2011;171(5):412-20.
21. Krolewski AS, Skupien J, Rossing P, Warram JH. Fast renal decline to end-stage renal disease: an unrecognized feature of nephropathy in diabetes. *Kidney Int*. 2017;91(6):1300-11.
22. Coresh J, Turin TC, Matsushita K, Sang Y, Ballew SH, Appel LJ, et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. *Jama*. 2014;311(24):2518-31.
23. Levey AS, Gansevoort RT, Coresh J, Inker LA, Heerspink HL, Grams ME, et al. Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency. *Am J Kidney Dis*. 2020;75(1):84-104.
24. Yamada T, Wakabayashi M, Bhalla A, Chopra N, Miyashita H, Mikami T, et al. Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis. *Cardiovasc Diabetol*. 2021;20(1):14.

**p10-14 Diabetic Kidney Disease – what's new? Cont'd**

25. Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Furtado RHM, et al. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. *Circulation*. 2019;139(17):2022-31.
26. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. *N Engl J Med*. 2019;380(24):2295-306.
27. Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertov GM, Greene T, Hou FF, et al. Dapagliflozin in Patients with Chronic Kidney Disease. *N Engl J Med*. 2020;383(15):1436-46.
28. Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, et al. Empagliflozin in Patients with Chronic Kidney Disease. *N Engl J Med*. 2023;388(2):117-27.
29. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. *N Engl J Med*. 2015;373(22):2117-28.
30. Adamson C, Docherty KF, Heerspink HJL, de Boer RA, Damman K, Inzucchi SE, et al. Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF. *Circulation*. 2022;146(6):438-49.
31. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2020. *Diabetes Care*. 2020;43(Suppl 1):S98-s110.
32. Perkins BA, Cherney DZ, Partridge H, Soleymanlou N, Tschirhart H, Zinman B, et al. Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. *Diabetes Care*. 2014;37(5):1480-3.
33. Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. *Cell Metab*. 2018;27(4):740-56.
34. Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. *Lancet*. 2019;394(10193):131-8.
35. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. *N Engl J Med*. 2016;375(19):1834-44.
36. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. *N Engl J Med*. 2016;375(4):311-22.
37. Cherney DZI, Udell JA, Drucker DJ. Cardiorenal mechanisms of action of glucagon-like-peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors. *Med (N Y)*. 2021;2(11):1203-30.
38. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. *N Engl J Med*. 2015;373(3):232-42.
39. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. *N Engl J Med*. 2013;369(14):1317-26.
40. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. *N Engl J Med*. 2013;369(14):1327-35.
41. Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, et al. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. *Jama*. 2019;321(1):69-79.
42. Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care*. 2018;41(12):2669-701.
43. Gunton JE, Cheung NW, Davis TM, Zoungas S, Colagiuri S. A new blood glucose management algorithm for type 2 diabetes: a position statement of the Australian Diabetes Society. *Med J Aust*. 2014;201(11):650-3.
44. Charytan DM, Solomon SD, Ivanovich P, Remuzzi G, Cooper ME, McGill JB, et al. Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease. *Diabetes Obes Metab*. 2019;21(5):1199-208.
45. Kooy A, de Jager J, Lehert P, Bets D, Wulffélé MG, Donker AJ, et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. *Arch Intern Med*. 2009;169(6):616-25.

**p10-14 Diabetic Kidney Disease – what's new? Cont'd**

46. Bodmer M, Meier C, Krähenbühl S, Jick SS, Meier CR. Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis. *Diabetes Care*. 2008;31(11):2086-91.
47. Hung SC, Chang YK, Liu JS, Kuo KL, Chen YH, Hsu CC, et al. Metformin use and mortality in patients with advanced chronic kidney disease: national, retrospective, observational, cohort study. *Lancet Diabetes Endocrinol*. 2015;3(8):605-14.
48. D'Agati VD, Chagnac A, de Vries AP, Levi M, Porrini E, Herman-Edelstein M, et al. Obesity-related glomerulopathy: clinical and pathologic characteristics and pathogenesis. *Nat Rev Nephrol*. 2016;12(8):453-71.
49. Ladhani M, Craig JC, Irving M, Clayton PA, Wong G. Obesity and the risk of cardiovascular and all-cause mortality in chronic kidney disease: a systematic review and meta-analysis. *Nephrol Dial Transplant*. 2017;32(3):439-49.
50. Genuth S, Eastman R, Kahn R, Klein R, Lachin J, Lebovitz H, et al. Implications of the United Kingdom prospective diabetes study. *Diabetes Care*. 2003;26 Suppl 1:S28-32.
51. Alicic RZ, Rooney MT, Tuttle KR. Diabetic Kidney Disease: Challenges, Progress, and Possibilities. *Clin J Am Soc Nephrol*. 2017;12(12):2032-45.
52. Patney V, Whaley-Connell A, Bakris G. Hypertension Management in Diabetic Kidney Disease. *Diabetes Spectr*. 2015;28(3):175-80.
53. Chronic Kidney Disease (CKD) Management in Primary Care. 4th ed: Kidney Health Australia; 2020.
54. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. *N Engl J Med*. 2001;345(12):870-8.
55. Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. *N Engl J Med*. 2013;369(20):1892-903.
56. Mann JF, Anderson C, Gao P, Gerstein HC, Boehm M, Rydén L, et al. Dual inhibition of the renin-angiotensin system in high-risk diabetes and risk for stroke and other outcomes: results of the ONTARGET trial. *J Hypertens*. 2013;31(2):414-21.
57. Barrera-Chimal J, Girerd S, Jaisser F. Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis. *Kidney Int*. 2019;96(2):302-19.
58. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. *N Engl J Med*. 2020;383(23):2219-29.
59. Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. *N Engl J Med*. 2021;385(24):2252-63.
60. Agarwal R, Kolkhof P, Bakris G, Bauersachs J, Haller H, Wada T, et al. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. *Eur Heart J*. 2021;42(2):152-61.
61. Abrass CK. Lipid metabolism and renal disease. *Contrib Nephrol*. 2006;151:106-21.
62. Hirano T. Pathophysiology of Diabetic Dyslipidemia. *J Atheroscler Thromb*. 2018;25(9):771-82.
63. Wanner C, Tonelli M. KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient. *Kidney Int*. 2014;85(6):1303-9.
64. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. *Eur Heart J*. 2020;41(1):111-88.
65. Haynes R, Lewis D, Emberson J, Reith C, Agodoa L, Cass A, et al. Effects of lowering LDL cholesterol on progression of kidney disease. *J Am Soc Nephrol*. 2014;25(8):1825-33.
66. Palmer SC, Craig JC, Navaneethan SD, Tonelli M, Pellegrini F, Strippoli GF. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. *Ann Intern Med*. 2012;157(4):263-75.
67. Jun M, Zhu B, Tonelli M, Jardine MJ, Patel A, Neal B, et al. Effects of fibrates in kidney disease: a systematic review and meta-analysis. *J Am Coll Cardiol*. 2012;60(20):2061-71.
68. Keech AC, Mitchell P, Summanen PA, O'Day J, Davis TM, Moffitt MS, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. *Lancet*. 2007;370(9600):1687-97.
69. Gündoğdu Y, Anaforoğlu İ. Effects of Smoking on Diabetic Nephropathy. *Frontiers in Clinical Diabetes and Healthcare*. 2022 Feb 23;3.

## November 2023 References

### **p10-14 Diabetic Kidney Disease – what's new? Cont'd**

70. Huo L, Magliano DJ, Rancièrè F, Harding JL, Nanayakkara N, Shaw JE, et al. Impact of age at diagnosis and duration of type 2 diabetes on mortality in Australia 1997-2011. *Diabetologia*. 2018;61(5):1055-63.
71. Li FR, Yang HL, Zhou R, Zheng JZ, Chen GC, Zou MC, et al. Diabetes duration and glycaemic control as predictors of cardiovascular disease and mortality. *Diabetes Obes Metab*. 2021;23(6):1361-70.
72. Welfare AIH. Cardiovascular disease, diabetes and chronic kidney disease—Australian facts: Aboriginal and Torres Strait Islander people. Canberra; 2015.
73. National guide to a preventive health assessment for Aboriginal and Torres Strait Islander people: Evidence base Third edition [Internet]. Available from: <https://www.racgp.org.au/FSDEDEV/media/documents/Clinical%20Resources/Resources/Evidence-base-to-a-preventive-health-assessment-3rd-edition.pdf>

### **p17-19 The risk of obesity in pregnancy**

1. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. *The Lancet* [Internet]. 2004 Jan;363(9403):157–63. Available from: <https://pubmed.ncbi.nlm.nih.gov/14726171/>
2. AIHW. Overweight and obesity, Summary [Internet]. Australian Institute of Health and Welfare. 2023. Available from: <https://www.aihw.gov.au/reports/overweight-obesity/overweight-and-obesity/contents/overweight-and-obesity>
3. Widen EM, Gallagher D. Body composition changes in pregnancy: measurement, predictors and outcomes. *European Journal of Clinical Nutrition*. 2014 Mar 26;68(6):643–52.
4. Weight Gain During Pregnancy [Internet]. [www.acog.org](http://www.acog.org). 2020. Available from: <https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2013/01/weight-gain-during-pregnancy>
5. National Perinatal Data Collection (NPDC) [Internet]. Australian Institute of Health and Welfare. Available from: <https://www.aihw.gov.au/about-our-data/our-data-collections/national-perinatal-data-collection>
6. Robinson WR, Kershaw KN, Mezuk B, Rafferty J, Lee H, Johnson-Lawrence V, et al. Coming unmoored: Disproportionate increases in obesity prevalence among young, disadvantaged white women. *Obesity*. 2014 Oct 8;23(1):213–9.
7. Bjeremo H, Lind S, Rasmussen F. The educational gradient of obesity increases among Swedish pregnant women: a register-based study. *BMC Public Health*. 2015 Apr 1;15(1).
8. Bahadoer S, Gaillard R, Felix JF, Raat H, Renders CM, Hofman A, et al. Ethnic disparities in maternal obesity and weight gain during pregnancy. The Generation R Study. *European Journal of Obstetrics & Gynecology and Reproductive Biology* [Internet]. 2015 Oct [cited 2019 Sep 20];193:51–60. Available from: <http://europepmc.org/articles/PMC5408938/>
9. AIHW. Overweight and obesity, Summary [Internet]. Australian Institute of Health and Welfare. 2023. Available from: <https://www.aihw.gov.au/reports/overweight-obesity/overweight-and-obesity/contents/overweight-and-obesity>
10. Catalano PM, Hauguel-De Mouzon S. Is it time to revisit the Pedersen hypothesis in the face of the obesity epidemic? *American Journal of Obstetrics and Gynecology*. 2011 Jun;204(6):479–87.
11. Barbour LA. Metabolic Culprits in Obese Pregnancies and Gestational Diabetes Mellitus: Big Babies, Big Twists, Big Picture. *Diabetes Care*. 2019 Apr 22;42(5):718–26.
12. Friedman JE. Obesity and Gestational Diabetes Mellitus Pathways for Programming in Mouse, Monkey, and Man—Where Do We Go Next? The 2014 Norbert Freinkel Award Lecture. *Diabetes Care*. 2015 Jul 14;38(8):1402–11.
13. van Dijk SJ, Tellam RL, Morrison JL, Muhlhausler BS, Molloy PL. Recent developments on the role of epigenetics in obesity and metabolic disease. *Clinical Epigenetics* [Internet]. 2015 Jul 11;7(1). Available from: <https://clinicalepigeneticsjournal.biomedcentral.com/articles/10.1186/s13148-015-0101-5>
14. Lashen H. Obesity is associated with increased risk of first trimester and recurrent miscarriage: matched case-control study. *Human Reproduction*. 2004 Jul 1;19(7):1644–6.
15. Catalano PM, McIntyre HD, Cruickshank JK, McCance DR, Dyer AR, Metzger BE, et al. The Hyperglycemia and Adverse Pregnancy Outcome Study: Associations of GDM and obesity with pregnancy outcomes. *Diabetes Care*. 2012 Feb 22;35(4):780–6.

## November 2023 References

### **p17-19 The risk of obesity in pregnancy Cont'd**

16. Spradley FT. Metabolic abnormalities and obesity's impact on the risk for developing preeclampsia. *American Journal of Physiology-Regulatory, Integrative and Comparative Physiology*. 2017 Jan 1;312(1):R5–12.
17. Persson M, Cnattingius S, Villamor E, Söderling J, Pasternak B, Stephansson O, et al. Risk of major congenital malformations in relation to maternal overweight and obesity severity: cohort study of 1.2 million singletons. *BMJ [Internet]*. 2017 Jun 14;357. Available from: <https://www.bmj.com/content/357/bmj.j2563>
18. Rasmussen SA, Chu SY, Kim SY, Schmid CH, Lau J. Maternal obesity and risk of neural tube defects: a metaanalysis. *American Journal of Obstetrics and Gynecology*. 2008 Jun;198(6):611–9.
19. Arrowsmith S, Wray S, Quenby S. Maternal obesity and labour complications following induction of labour in prolonged pregnancy. *BJOG: An International Journal of Obstetrics & Gynaecology*. 2011 Jan 26;118(5):578–88.
20. Chu SY, Kim SY, Schmid CH, Dietz PM, Callaghan WM, Lau J, et al. Maternal obesity and risk of cesarean delivery: a meta-analysis. *Obesity Reviews*. 2007 Sep;8(5):385–94.
21. Cnattingius S, Villamor E, Johansson S, et al. Maternal obesity and risk of preterm delivery. *JAMA*. Jun 2013;309(22):2362-70. doi:10.1001/jama.2013.6295
22. Aune D, Saugstad OD, Henriksen T, Tonstad S. Maternal body mass index and the risk of fetal death, stillbirth, and infant death: a systematic review and meta-analysis. *JAMA*. Apr 2014;311(15):1536-46. doi:10.1001/jama.2014.2269
23. Stamilio DM, Scifres CM. Extreme obesity and postcesarean maternal complications. *Obstet Gynecol*. Aug 2014;124(2 Pt 1):227-32. doi:10.1097/AOG.0000000000000384
24. Amir LH, Donath S. A systematic review of maternal obesity and breastfeeding intention, initiation and duration. *BMC Pregnancy Childbirth*. Jul 2007;7:9. doi:10.1186/1471-2393-7-9
25. Ma RC, Schmidt MI, Tam WH, McIntyre HD, Catalano PM. Clinical management of pregnancy in the obese mother: before conception, during pregnancy, and post partum. *Lancet Diabetes Endocrinol*. Dec 2016;4(12):1037-1049. doi:10.1016/S2213-8587(16)30278-9
26. Whitaker RC. Predicting preschooler obesity at birth: the role of maternal obesity in early pregnancy. *Pediatrics*. Jul 2004;114(1):e29-36.
27. Zhu Y, Olsen SF, Mendola P, et al. Growth and obesity through the first 7 y of life in association with levels of maternal glycemia during pregnancy: a prospective cohort study. *Am J Clin Nutr*. Mar 2016;103(3):794-800. doi:10.3945/ajcn.115.121780
28. Patro Golab B, Santos S, Voerman E, et al. Influence of maternal obesity on the association between common pregnancy complications and risk of childhood obesity: an individual participant data meta-analysis. *Lancet Child Adolesc Health*. 11 2018;2(11):812-821. doi:10.1016/S2352-4642(18)30273-6
29. Lowe WL, Scholtens DM, Lowe LP, et al. Association of Gestational Diabetes With Maternal Disorders of Glucose Metabolism and Childhood Adiposity. *JAMA*. 09 2018;320(10):1005-1016. doi:10.1001/jama.2018.11628
30. Sanchez CE, Barry C, Sabhlok A, et al. Maternal pre-pregnancy obesity and child neurodevelopmental outcomes: a meta-analysis. *Obes Rev*. Apr 2018;19(4):464-484. doi:10.1111/obr.12643
31. Lee KK, Raja EA, Lee AJ, et al. Maternal Obesity During Pregnancy Associates With Premature Mortality and Major Cardiovascular Events in Later Life. *Hypertension*. Nov 2015;66(5):938-44. doi:10.1161/HYPERTENSIONAHA.115.05920
32. Lee AJ, Hiscock RJ, Wein P, Walker SP, Permezel M. Gestational diabetes mellitus: clinical predictors and long-term risk of developing type 2 diabetes: a retrospective cohort study using survival analysis. *Diabetes Care*. Apr 2007;30(4):878-83. doi:10.2337/dc06-1816
33. Beharier O, Shoham-Vardi I, Pariente G, et al. Gestational diabetes mellitus is a significant risk factor for long-term maternal renal disease. *J Clin Endocrinol Metab*. Apr 2015;100(4):1412-6. doi:10.1210/jc.2014-4474
34. Appiah D, Schreiner PJ, Gunderson EP, et al. Association of Gestational Diabetes Mellitus With Left Ventricular Structure and Function: The CARDIA Study. *Diabetes Care*. Mar 2016;39(3):400-7. doi:10.2337/dc15-1759
35. Management of Obesity in Pregnancy [Internet]. Available from: <https://ranzcog.edu.au/wp-content/uploads/2022/05/Management-of-Obesity-in-Pregnancy.pdf>

**p17-19 The risk of obesity in pregnancy Cont'd**

36. Dubois L, Diasparra M, Bédard B, et al. Adequacy of nutritional intake during pregnancy in relation to prepregnancy BMI: results from the 3D Cohort Study. *Br J Nutr.* Aug 2018;120(3):335-344. doi:10.1017/S0007114518001393
37. Australian Government Department of Health. Pregnancy Care Guidelines [Internet]. Australian Government Department of Health. 2018. Available from: <https://www.health.gov.au/resources/pregnancy-care-guide>
38. Wing RR, Hill JO. Successful weight loss maintenance. *Annu Rev Nutr.* 2001;21:323-41. doi:10.1146/annurev.nutr.21.1.323
39. Zozzaro-Smith P, Gray LM, Bacak SJ, Thornburg LL. Limitations of Aneuploidy and Anomaly Detection in the Obese Patient. *J Clin Med.* Jul 17 2014;3(3):795-808. doi:10.3390/jcm3030795
40. Juul LA, Hartwig TS, Ambye L, Sørensen S, Jørgensen FS. Noninvasive prenatal testing and maternal obesity: A review. *Acta Obstet Gynecol Scand.* Jun 2020;99(6):744-750. doi:10.1111/aogs.13848
41. Landon MB, Spong CY, Thom E, et al. A multicenter, randomized trial of treatment for mild gestational diabetes. *N Engl J Med.* Oct 2009;361(14):1339-48. doi:10.1056/NEJMoa0902430
42. Crowther CA, Hiller JE, Moss JR, et al. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. *N Engl J Med.* Jun 2005;352(24):2477-86. doi:10.1056/NEJMoa042973
43. Best KE, Tennant PW, Bell R, Rankin J. Impact of maternal body mass index on the antenatal detection of congenital anomalies. *BJOG.* Nov 2012;119(12):1503-11. doi:10.1111/j.1471-0528.2012.03462.x

**Useful Resources:**

World Obesity: [www.worldobesity.org/news/obesity-and-pregnancy](http://www.worldobesity.org/news/obesity-and-pregnancy)

RACP: [racp-obesity-position-statement.pdf](http://racp-obesity-position-statement.pdf)

RANZCOG: [www.ranzcog.edu.au/wp-content/uploads/2022/05/Management-of-Obesity-in-Pregnancy.pdf](http://www.ranzcog.edu.au/wp-content/uploads/2022/05/Management-of-Obesity-in-Pregnancy.pdf)

Australian Breast Feeding Association: [www.breastfeeding.asn.au](http://www.breastfeeding.asn.au)

Guidelines for VTE in pregnancy and the post-partum period:

<http://onlinelibrary.wiley.com/doi/10.1111/j.1479-828X.2011.01361.x/full>

**p20-23 The role of exercise in the management of DKD**

1. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease kidney INTERNATIONALSUPPLEMENTTO [Internet]. Available from: <https://kdigo.org/wp-content/uploads/2022/10/KDIGO-2022-Clinical-Practice-Guideline-for-Diabetes-Management-in-CKD.pdf>
2. Katzmarzyk PT, Friedenreich C, Shiroma EJ, Lee IM. Physical inactivity and non-communicable disease burden in low-income, middle-income and high-income countries. *Br J Sports Med.* 2022;56(2):101-6.
3. Zelle DM, Klaassen G, van Adrichem E, Bakker SJ, Corpeleijn E, Navis G. Physical inactivity: a risk factor and target for intervention in renal care. *Nat Rev Nephrol.* 2017;13(5):318.
4. Amaral LSB, Souza CS, Lima HN, Soares TJ. Influence of exercise training on diabetic kidney disease: A brief physiological approach. *Exp Biol Med (Maywood).* 2020;245(13):1142-54.
5. Bishop NC, Burton JO, Graham-Brown MPM, Stensel DJ, Viana JL, Watson EL. Exercise and chronic kidney disease: potential mechanisms underlying the physiological benefits. *Nat Rev Nephrol.* 2023;19(4):244-56.
6. Williams A, Radford J, O'Brien J, Davison K. Type 2 diabetes and the medicine of exercise: The role of general practice in ensuring exercise is part of every patient's plan. *Australian Journal for General Practitioners.* 2020;49:189-93.
7. Baker LA, March DS, Wilkinson TJ, Billany RE, Bishop NC, Castle EM, et al. Clinical practice guideline exercise and lifestyle in chronic kidney disease. *BMC Nephrol.* 2022;23(1):75.
8. Look ARG. Effect of a long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: a secondary analysis of the Look AHEAD randomised clinical trial. *Lancet Diabetes Endocrinol.* 2014;2(10):801-9.
9. Clyne N, Anding-Rost K. Exercise training in chronic kidney disease-effects, expectations and adherence. *Clin Kidney J.* 2021;14(Suppl 2):ii3-ii14.
10. Clarke AL, Jhamb M, Bennett PN. Barriers and facilitators for engagement and implementation of exercise in end-stage kidney disease: Future theory-based interventions using the Behavior Change Wheel. *Semin Dial.* 2019;32(4):308-19.

**p20-23 The role of exercise in the management of DKD Cont'd**

11. Umpierre D, Ribeiro PA, Kramer CK, Leitao CB, Zucatti AT, Azevedo MJ, et al. Physical activity advice only or structured exercise training and association with HbA1c levels in type 2 diabetes: a systematic review and meta-analysis. *JAMA*. 2011;305(17):1790-9.
12. Jayedi A, Emadi A, Shab-Bidar S. Dose-Dependent Effect of Supervised Aerobic Exercise on HbA1c in Patients with Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials. *Sports Medicine*. 2022;52(8):1919-38.
13. Watson EL, Viana JL, Wimbury D, Martin N, Greening NJ, Barratt J, et al. The Effect of Resistance Exercise on Inflammatory and Myogenic Markers in Patients with Chronic Kidney Disease. *Front Physiol*. 2017;8:541.
14. Cardoso DF, Marques EA, Leal DV, Ferreira A, Baker LA, Smith AC, et al. Impact of physical activity and exercise on bone health in patients with chronic kidney disease: a systematic review of observational and experimental studies. *BMC Nephrol*. 2020;21(1):334.
15. Streckmann F, Balke M, Cavaletti G, Toscanelli A, Bloch W, Décard BF, et al. Exercise and Neuropathy: Systematic Review with Meta-Analysis. *Sports Medicine*. 2022;52(5):1043-65.
16. Avesani CM, Trolonge S, Deleaval P, Baria F, Mafra D, Faxen-Irving G, et al. Physical activity and energy expenditure in haemodialysis patients: an international survey. *Nephrology Dialysis Transplantation*. 2011 Dec 15;27(6):2430-4.
17. Mohammad Ali Tabibi, Cheema B, Nasrin Salimian, Hugo, Ahmadi S. The effect of intradialytic exercise on dialysis patient survival: a randomized controlled trial. 2023 Apr 17;24(1).
18. Graham-Brown MPM, March DS, Young R, Highton PJ, Young HML, Churchward DR, et al. A randomized controlled trial to investigate the effects of intra-dialytic cycling on left ventricular mass. *Kidney International*. 2021 Jun;99(6):1478-86.
19. Bennett PN, Bohm C, Harasemiw O, Brown L, Gabrys I, Jegatheesan D, et al. Physical activity and exercise in peritoneal dialysis: International Society for Peritoneal Dialysis and the Global Renal Exercise Network practice recommendations. *Perit Dial Int*. 2022;42(1):8-24.
20. Vuori IM, Lavie CJ, Blair SN. Physical activity promotion in the health care system. *Mayo Clin Proc*. 2013;88(12):1446-61.
21. Rees S, Williams A. Promoting and supporting self-management for adults living in the community with physical chronic illness: A systematic review of the effectiveness and meaningfulness of the patient-practitioner encounter. *JBI Libr Syst Rev*. 2009;7(13):492-582.
22. Baker LA, March DS, Wilkinson TJ, Billany RE, Bishop NC, Castle EM, et al. Clinical practice guideline exercise and lifestyle in chronic kidney disease. *BMC Nephrol*. 2022;23(1):75.
23. Turner G, Quigg S, Davoren P, Basile R, McAuley SA, Coombes JS. Resources to Guide Exercise Specialists Managing Adults with Diabetes. *Sports Med Open*. 2019;5(1):20.
24. Clarke AL, Young HML, Hull KL, Hudson N, Burton JO, Smith AC. Motivations and barriers to exercise in chronic kidney disease: a qualitative study. *Nephrology Dialysis Transplantation*. 2015;30(11):1885-92.
25. Zale EL, Ditre JW. Pain-Related Fear, Disability, and the Fear-Avoidance Model of Chronic Pain. *Curr Opin Psychol*. 2015;5:24-30.
26. Flavel J, McKee M, Tesfay FH, Musolino C, Freeman T, van Eyk H, et al. Explaining health inequalities in Australia: the contribution of income, wealth and employment. *Aust J Prim Health*. 2022;28(6):474-81.

**p24 – 27 Diabetes emergencies**

1. Glaser N, Fritsch M, Priyambada L, et al. ISPAD Clinical Practice Consensus Guidelines 2022: Diabetic ketoacidosis and hyperglycemic hyperosmolar state. *Pediatric Diabetes* 2022;23(7):835-56. doi: <https://doi.org/10.1111/pedi.13406>
2. Birkebaek NH, Kamrath C, Grimsmann JM, et al. Impact of the COVID-19 pandemic on long-term trends in the prevalence of diabetic ketoacidosis at diagnosis of paediatric type 1 diabetes: an international multicentre study based on data from 13 national diabetes registries. *Lancet Diabetes Endocrinol* 2022;10(11):786-94. doi: 10.1016/s2213-8587(22)00246-7 [published Online First: 20221003]
3. Rodrigues F, O'Connell MA, White M. A point-of-care test increases same-day referral and reduces DKA in children with new-onset type 1 diabetes. *Australian journal of general practice* 2021;50(4):246-51.
4. Atlas G, Rodrigues F, Moshage Y, et al. PRESENTATION OF PAEDIATRIC TYPE 1 DIABETES IN MELBOURNE, AUSTRALIA DURING THE INITIAL STAGES OF THE COVID-19 PANDEMIC. *J Paediatr Child Health* 2020;56(10):1654-55. doi: 10.1111/jpc.15081 [published Online First: 20200922]



**p24 – 27 Diabetes emergencies Cont'd**

5. Huang A, Chen Q, Yang W, et al. Clinical characteristics of 683 children and adolescents, aged 0–18 years, newly diagnosed with type 1 diabetes mellitus in Henan Province: a single-center study. *BMC Pediatrics* 2023;23(1):39. doi: 10.1186/s12887-023-03847-z
6. Aye T, Mazaika PK, Mauras N, et al. Impact of Early Diabetic Ketoacidosis on the Developing Brain. *Diabetes Care* 2019;42(3):443-49. doi: 10.2337/dc18-1405 [published Online First: 20181220]
7. Craig ME, Wong CH, Alexander J, et al. Delayed referral of new-onset type 1 diabetes increases the risk of diabetic ketoacidosis. *Med J Aust* 2009;190(4):219. doi: 10.5694/j.1326-5377.2009.tb02356.x
8. Fleming N, Hamblin PS, Story D, et al. Evolving Evidence of Diabetic Ketoacidosis in Patients Taking Sodium-Glucose Cotransporter 2 Inhibitors. *The Journal of clinical endocrinology and metabolism* 2020;105(8) doi: 10.1210/clinem/dgaa200 [published Online First: 2020/04/18]
9. Pasquel FJ, Umpierrez GE. Hyperosmolar hyperglycemic state: a historic review of the clinical presentation, diagnosis, and treatment. *Diabetes care* 2014;37(11):3124-31. doi: 10.2337/dc14-0984 [published Online First: 2014/10/25]
10. Pasquel FJ, Tsegka K, Wang H, et al. Clinical Outcomes in Patients With Isolated or Combined Diabetic Ketoacidosis and Hyperosmolar Hyperglycemic State: A Retrospective, Hospital-Based Cohort Study. *Diabetes care* 2020;43(2):349-57. doi: 10.2337/dc19-1168 [published Online First: 2019/11/11]
11. Health ALO, Welfare. Diabetic ketoacidosis (DKA) among children and young people with type 1 diabetes. Canberra: AIHW, 2016.
12. Venkatesh B, Pilcher D, Prins J, et al. Incidence and outcome of adults with diabetic ketoacidosis admitted to ICUs in Australia and New Zealand. *Crit Care* 2015;19:451. doi: 10.1186/s13054-015-1171-7 [published Online First: 20151229]
13. Willix C, Griffiths E, Singleton S. RACGP - Hyperglycaemic presentations in type 2 diabetes [Internet]. *Racgp.org.au*. 2020. Available from: <https://www1.racgp.org.au/ajgp/2019/may/hyperglycaemic-presentations-in-type-2-diabetes>
14. Rugg-Gunn CEM, Dixon E, Jorgensen AL, et al. Factors Associated With Diabetic Ketoacidosis at Onset of Type 1 Diabetes Among Pediatric Patients: A Systematic Review. *JAMA Pediatrics* 2022;176(12):1248-59. doi: 10.1001/jamapediatrics.2022.3586
15. Usher-Smith JA, Thompson MJ, Sharp SJ, et al. Factors associated with the presence of diabetic ketoacidosis at diagnosis of diabetes in children and young adults: a systematic review. *BMJ* 2011;343:d4092. doi: 10.1136/bmj.d4092
16. Ehrmann D, Kulzer B, Roos T, et al. Risk factors and prevention strategies for diabetic ketoacidosis in people with established type 1 diabetes. *The Lancet Diabetes & Endocrinology* 2020;8(5):436-46. doi: [https://doi.org/10.1016/S2213-8587\(20\)30042-5](https://doi.org/10.1016/S2213-8587(20)30042-5)
17. Große J, Hornstein H, Manuwald U, et al. Incidence of Diabetic Ketoacidosis of New-Onset Type 1 Diabetes in Children and Adolescents in Different Countries Correlates with Human Development Index (HDI): An Updated Systematic Review, Meta-Analysis, and Meta-Regression. *Horm Metab Res* 2018;50(3):209-22. doi: 10.1055/s-0044-102090 [published Online First: 20180309]
18. Baloch SH, Ibrahim PMN, Lohano PD, et al. Pediatric Risk of Mortality III Score in Predicting Mortality Among Diabetic Ketoacidosis Patients in a Pediatric Intensive Care Unit. *Cureus* 2021;13(11):e19734. doi: 10.7759/cureus.19734 [published Online First: 20211119]
19. Dhatariya KK, Glaser NS, Codner E, et al. Diabetic ketoacidosis. *Nature Reviews Disease Primers* 2020;6(1):40. doi: 10.1038/s41572-020-0165-1
20. Willix C, Griffiths E, Singleton S. Hyperglycaemic presentations in type 2 diabetes. *Australian Journal for General Practitioners* 2019;48:163-67.
21. Willix C, Griffiths E, Singleton S. Hyperglycaemic presentations in type 2 diabetes. *Australian journal of general practice* 2019;48(5):263-67. doi: 10.31128/ajgp-12-18-4785 [published Online First: 2019/05/28]
22. Westerberg DP. Diabetic ketoacidosis: evaluation and treatment. *Am Fam Physician* 2013;87(5):337-46.
23. Kahanovitz L, Sluss PM, Russell SJ. Type 1 Diabetes - A Clinical Perspective. *Point Care* 2017;16(1):37-40. doi: 10.1097/poc.000000000000125
24. Dr JAMN, Barlow J, Price S, Shaw J, Twigg S. Emergency management of hyperglycaemia in primary care RACGP and ADS joint clinical position statement Working group members [Internet]. 2018. Available from: <https://www.racgp.org.au/FSDEDEV/media/documents/Clinical%20Resources/Guidelines/Management-of-hyperglycaemia.pdf>.

**p24 – 27 Diabetes Emergencies**

25. Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic Crises in Adult Patients With Diabetes. *Diabetes Care* [Internet]. 2009 Jun 29;32(7):1335–43. Available from: <https://diabetesjournals.org/care/article/32/7/1335/27093/Hyperglycemic-Crises-in-Adult-Patients-With>
26. Shen E, Koyama SY, Huynh DN, et al. Association of a Dedicated Post-Hospital Discharge Follow-up Visit and 30-Day Readmission Risk in a Medicare Advantage Population. *JAMA Intern Med* 2017;177(1):132-35. doi: 10.1001/jamainternmed.2016.7061 [published Online First: 2016/11/29]
27. Kimbell B, Lawton J, Boughton C, et al. Parents' experiences of caring for a young child with type 1 diabetes: a systematic review and synthesis of qualitative evidence. *BMC Pediatrics* 2021;21(1):160. doi: 10.1186/s12887-021-02569-4
28. Hare MJL, Deitch JM, Kang MJY, et al. Clinical, psychological and demographic factors in a contemporary adult cohort with diabetic ketoacidosis and type 1 diabetes. *Intern Med J* 2021;51(8):1292-97. doi: 10.1111/imj.14877 [published Online First: 2020/05/03]
29. James S, Annetts K, Frakking T, et al. Hospital presentations with diabetic ketoacidosis: A retrospective review. *Australasian Emergency Care* 2023;26(1):1-6. doi: <https://doi.org/10.1016/j.auec.2022.06.001>
30. James S, Annetts K, Frakking T, et al. Diabetic ketoacidosis presentations in a low socio-economic area: are services suitable? *BMC Health Services Research* 2021;21(1):682. doi: 10.1186/s12913-021-06715-7
31. Glans M, Kragh Ekstam A, Jakobsson U, et al. Risk factors for hospital readmission in older adults within 30 days of discharge – a comparative retrospective study. *BMC Geriatrics* 2020;20(1):467. doi: 10.1186/s12877-020-01867-3
32. Clinical Guiding Principles for Sick Day Management of Adults with Type 1 Diabetes or Type 2 Diabetes A Guide for Health Professionals [Internet]. 2020. Available from: [https://www.adea.com.au/wp-content/uploads/2020/09/Sickdays-\\_12.pdf](https://www.adea.com.au/wp-content/uploads/2020/09/Sickdays-_12.pdf)

**p28 – 31 PCOS: nutrition & lifestyle recommendations**

1. Gilbert EW, Tay CT, Hiam DS, Teede H, Moran LJ. Comorbidities and complications of polycystic ovary syndrome: an overview of systematic reviews. *Clin Endocrinol (Oxf)*. August 2018. doi:10.1111/cen.13828
2. Lim SS, Davies MJ, Norman RJ, Moran LJ. Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. *Hum Reprod Update*. 2012;18(6):618-637. doi:10.1093/humupd/dms030
3. Lim SS, Norman RJ, Davies MJ, Moran LJ. The effect of obesity on polycystic ovary syndrome: a systematic review and meta-analysis. *Obes Rev*. 2013;14(2):95-109. doi:10.1111/j.1467-789X.2012.01053.x
4. Teede H et al on behalf of the IPN. International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome 2023.; 2023. <https://www.monash.edu/medicine/mchri/pcos/guideline>.
5. Lau GM, Elghobashy M, Thanki M, et al. A systematic review of lived experiences of people with polycystic ovary syndrome highlights the need for holistic care and co-creation of educational resources. *Front Endocrinol (Lausanne)*. 2022;13. doi:10.3389/FENDO.2022.1064937
6. Mallappa Saroja CS, Hanji Chandrashekar S. Polycystic ovaries: review of medical information on the internet for patients. *Arch Gynecol Obstet*. 2010;281(5):839-843. doi:10.1007/S00404-010-1378-4
7. Naude CE, Brand A, Schoonees A, Nguyen KA, Chaplin M, Volmink J. Low-carbohydrate versus balanced-carbohydrate diets for reducing weight and cardiovascular risk. *Cochrane database Syst Rev*. 2022;1(1). doi:10.1002/14651858.CD013334.PUB2
8. Ge L, Sadeghirad B, Ball GDC, et al. Comparison of dietary macronutrient patterns of 14 popular named dietary programmes for weight and cardiovascular risk factor reduction in adults: systematic review and network meta-analysis of randomised trials. *BMJ*. 2020;369. doi:10.1136/BMJ.M696
9. Australian Government Department of Health and Aged Care. Physical activity and exercise guidelines for all Australians. <https://www.health.gov.au/topics/physical-activity-and-exercise/physical-activity-and-exercise-guidelines-for-all-australians>. Accessed August 26, 2023.
10. Gibson-Helm M, Teede H, Dunaif A, Dokras A. Delayed diagnosis and a lack of information associated with dissatisfaction in women with polycystic ovary syndrome. *J Clin Endocrinol Metab*. 2016;102(2):jc.2016-2963. doi:10.1210/jc.2016-2963

**p32-34 Dietary management of diabetic kidney disease**

1. Lambert K, Mansfield K, Mullan J. How do patients and carers make sense of renal dietary advice? A qualitative exploration. *Journal of Renal Care*. 2018 Sep 27;44(4):238–50.
2. Palmer SC, Hanson CS, Craig JC, Strippoli GFM, Ruospo M, Campbell K, et al. Dietary and Fluid Restrictions in CKD: A Thematic Synthesis of Patient Views From Qualitative Studies. *American Journal of Kidney Diseases*. 2015 Apr;65(4):559–73.
3. Notaras S, Lambert K, Perz J, Makris A. Diet in the management of non-dialysis dependent chronic kidney disease: perceptions and practices of health professionals. *BMC Nephrology*. 2022;23(1):158.
4. Neale EP, Middleton J, Lambert K. Barriers and enablers to detection and management of chronic kidney disease in primary healthcare: a systematic review. *BMC Nephrology*. 2020;21(1):83.
5. Lambert K, Mansfield K, Mullan J. Qualitative exploration of the experiences of renal dietitians and how they help patients with end stage kidney disease to understand the renal diet. *Nutr Diet*. 2019;76(2):126-34.
6. Ikizler TA, Burrowes JD, Byham-Gray LD, Campbell KL, Carrero JJ, Chan W, et al. KDOQI Clinical Practice Guideline for Nutrition in CKD: 2020 Update. *American journal of kidney diseases : the official journal of the National Kidney Foundation*. 2020;76(3 Suppl 1):S1-s107.
7. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. *Kidney international*. 2022;102(5s):S1-s127.
8. Aas A-M, Axelsen M, Churuangsuk C, Hermansen K, Kendall CWC, Kahleova H, et al. Evidence-based European recommendations for the dietary management of diabetes. *Diabetologia*. 2023;66(6):965-85.
9. Palmer SC, Maggo JK, Campbell KL, Craig JC, Johnson DW, Sutanto B, et al. Dietary interventions for adults with chronic kidney disease. *Cochrane Database of Systematic Reviews*. 2017;2017(4).
10. Sulaiman MK. Diabetic nephropathy: recent advances in pathophysiology and challenges in dietary management. *Diabetology & Metabolic Syndrome*. 2019;11(1):7.
11. Kalantar-Zadeh K, Fouque D. Nutritional Management of Chronic Kidney Disease. *New England Journal of Medicine*. 2017;377(18):1765-76.
12. KDIGO 2023 CLINICAL PRACTICE GUIDELINE FOR THE EVALUATION AND MANAGEMENT OF CHRONIC KIDNEY DISEASE PUBLIC REVIEW DRAFT [Internet]. 2023. Available from: [https://kdigo.org/wp-content/uploads/2017/02/KDIGO-2023-CKD-Guideline-Public-Review-Draft\\_5-July-2023.pdf](https://kdigo.org/wp-content/uploads/2017/02/KDIGO-2023-CKD-Guideline-Public-Review-Draft_5-July-2023.pdf)
13. Kalantar-Zadeh K, Jafar TH, Nitsch D, Neuen BL, Perkovic V. Chronic kidney disease. *Lancet*. 2021;398(10302):786-802.
14. Kelly JT, Su G, Zhang L, Qin X, Marshall S, González-Ortiz A, et al. Modifiable Lifestyle Factors for Primary Prevention of CKD: A Systematic Review and Meta-Analysis. *J Am Soc Nephrol*. 2021;32(1):239-53.
15. Bach KE, Kelly JT, Palmer SC, Khalesi S, Strippoli GF, Campbell KL. Healthy dietary patterns and incidence of CKD: a meta-analysis of cohort studies. *Clinical journal of the American Society of Nephrology: CJASN*. 2019;14(10):1441.
16. Kelly JT, Palmer SC, Wai SN, Ruospo M, Carrero JJ, Campbell KL, et al. Healthy Dietary Patterns and Risk of Mortality and ESRD in CKD: A Meta-Analysis of Cohort Studies. *Clin J Am Soc Nephrol*. 2017;12(2):272-9.
17. NHMRC. Nutrient Reference Values for Australia and New Zealand Including Recommended Dietary Intakes | NHMRC [Internet]. [www.nhmrc.gov.au](http://www.nhmrc.gov.au). 2006. Available from: <https://www.nhmrc.gov.au/about-us/publications/nutrient-reference-values-australia-and-new-zealand-including-recommended-dietary-intakes>
18. Kalantar-Zadeh K, Joshi S, Schlueter R, Cooke J, Brown-Tortorici A, Donnelly M, et al. Plant-Dominant Low-Protein Diet for Conservative Management of Chronic Kidney Disease. *Nutrients*. 2020;12(7).
19. Joshi S, Babich JS, Shen J, Kalantar-Zadeh K. Piecing Together the Potassium Puzzle: The Weak Association Between Dietary Potassium and Hyperkalemia. *Kidney International Reports*. 2023;8(3):403-4.
20. Picard K. Potassium Additives and Bioavailability: Are We Missing Something in Hyperkalemia Management? *Journal of Renal Nutrition*. 2019;29(4):350-3.
21. Stone MS, Martyn L, Weaver CM. Potassium Intake, Bioavailability, Hypertension, and Glucose Control. *Nutrients*. 2016;8(7).
22. Lambert K, Bird L, Borst AC, Fuller A, Wang Y, Rogers GB, et al. Safety and Efficacy of Using Nuts to Improve Bowel Health in Hemodialysis Patients. *J Ren Nutr*. 2020;30(5):462-9.
23. Clegg DJ, Gallant KMH. Plant-based diets in CKD. *Clinical journal of the American Society of Nephrology: CJASN*. 2019;14(1):141.

## November 2023 References

**p32-34 Dietary management of diabetic kidney disease Cont'd**

24. Carrero JJ, González-Ortiz A, Avesani CM, Bakker SJL, Bellizzi V, Chauveau P, et al. Plant-based diets to manage the risks and complications of chronic kidney disease. *Nature Reviews Nephrology*. 2020;16(9):525-42.
25. Joshi S, McMacken M, Kalantar-Zadeh K. Plant-based diets for kidney disease: a guide for clinicians. *American Journal of Kidney Diseases*. 2021;77(2):287-96.
26. Hemler EC, Hu FB. Plant-based diets for personal, population, and planetary health. *Advances in Nutrition*. 2019;10(Supplement\_4):S275-S83.
27. Craig WJ, Mangels AR, Fresán U, Marsh K, Miles FL, Saunders AV, et al. The safe and effective use of plant-based diets with guidelines for health professionals. *Nutrients*. 2021;13(11):4144.
28. Goraya N, Simoni J, Jo CH, Wesson DE. Treatment of metabolic acidosis in patients with stage 3 chronic kidney disease with fruits and vegetables or oral bicarbonate reduces urine angiotensinogen and preserves glomerular filtration rate. *Kidney international*. 2014;86(5):1031-8.
29. Goraya N, Simoni J, Jo CH, Wesson DE. A comparison of treating metabolic acidosis in CKD stage 4 hypertensive kidney disease with fruits and vegetables or sodium bicarbonate. *Clin J Am Soc Nephrol*. 2013;8(3):371-81.
30. Morrison R, Stanford J, Lambert K. Dietary Modelling to Explore the Impact of Potassium Chloride Replacement for Sodium in Bread for Adults with Chronic Kidney Disease. *Nutrients*. 2021;13(7).
31. Tapsell LC, Neale EP, Satija A, Hu FB. Foods, Nutrients, and Dietary Patterns: Interconnections and Implications for Dietary Guidelines. *Advances in Nutrition*. 2016;7(3):445-54.
32. Aguilera JM. The food matrix: implications in processing, nutrition and health. *Critical reviews in food science and nutrition*. 2019;59(22):3612-29.
33. Conley MM, McFarlane CM, Johnson DW, Kelly JT, Campbell KL, MacLaughlin HL. Interventions for weight loss in people with chronic kidney disease who are overweight or obese. *Cochrane Database Syst Rev*. 2021;3(3):Cd013119.
34. Juray S, Axen KV, Trasino SE. Remission of Type 2 Diabetes with Very Low-Calorie Diets-A Narrative Review. *Nutrients*. 2021;13(6).
35. Lambert K, Beer J, Dumont R, Hewitt K, Manley K, Meade A, et al. Weight management strategies for those with chronic kidney disease: A consensus report from the Asia Pacific Society of Nephrology and Australia and New Zealand Society of Nephrology 2016 renal dietitians meeting. *Nephrology*. 2018;23(10):912-20.
36. <https://support.easydietdiary.com/hc/en-us>

-- ENDS --